The COVID-19 Pandemic and Changes in Cancer Screening Disparities from 2015 to 2023: An NSHAP Survey Study
-
By
-
Lahari Vuppaladhadiam
-
Kristen Wroblewski
-
Phil Schumm
-
Jasmin Tiro
-
Louise Hawkley
-
Martha McClintock
-
Elbert S. Huang
-
July 16, 2026
Clinical Scorecard: Impact of the COVID-19 Pandemic on Cancer Screening Disparities from 2015 to 2023: Findings from the NSHAP Survey
At a Glance
| Category | Detail |
|---|
| Condition | Cancer Screening Disparities |
| Key Mechanisms | Impact of COVID-19 on healthcare access and changes in screening guidelines. |
| Target Population | Middle-aged and older adults, particularly those in marginalized communities. |
| Care Setting | Nationally representative longitudinal study. |
Key Highlights
- Cancer screening rates for breast and colorectal cancer increased from 1990 to 2020.
- Certain subpopulations, including Hispanic and Black individuals, have lower screening rates.
- COVID-19 pandemic led to significant delays in cancer screenings.
- US Preventive Services Task Force guidelines for CRC and prostate cancer screening changed during the study period.
- Longitudinal analysis utilized NSHAP data from 2015-2023.
Guideline-Based Recommendations
Diagnosis
- Screening for colorectal cancer recommended starting at age 45 as of 2021.
Management
- Consultation for prostate specific antigen (PSA) testing recommended for individuals aged 55-69.
Monitoring & Follow-up
- Past-year screening status assessed through surveys.
Risks
- Delays in screening may exacerbate health disparities in marginalized communities.
Patient & Prescribing Data
Middle-aged and older adults, particularly those aged 50 and above.
Screening rates for colonoscopies, mammograms, and PSA testing were analyzed.
Clinical Best Practices
- Encourage timely cancer screenings, especially in at-risk populations.
- Monitor changes in screening guidelines and adapt practices accordingly.
- Address socioeconomic and educational barriers to improve screening rates.
Related Resources & Content
